Trials / Terminated
TerminatedNCT01123304
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
A Phase 1 Clinical Trial of Intra-Tumoral Injection of Human IgM Monoclonal Antibody (MORAb-028) to the Ganglioside GD2 in Subjects With Injectable Metastatic Melanoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Morphotek · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MORAb028 | 1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26. |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2010-05-14
- Last updated
- 2014-07-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01123304. Inclusion in this directory is not an endorsement.